Key facts
- Prenuvo’s last known valuation is $600.0M (Feb 2025).
- It has raised $191.8M across 1 recorded rounds; the latest was Later Stage VC ($85.0M) in Jun 2024.
- Notable investors include StartX (US), BDC Capital, Felicis, Caffeinated Capital, Operator Partners — 18 tracked in total.
- Prenuvo has filed 1 Form D with the SEC, most recently Feb 2025 ($85.0M sold to 13 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Prenuvo
Funding rounds
1 roundsAbout Prenuvo
Developer of a whole-body magnetic resonance imaging scan technology designed for precision medicine, bringing quantitative reproducibility to radiology. The company's technology offers a range of multiparametric Magnetic resonance imaging techniques for cancer, brain, thoracic, abdomen, liver, reproductive organ, and spine-related diagnostics, enabling patients and pharmaceutical companies to have a clinically accurate and affordable way to detect early symptoms.
- Sector
- Healthcare
- HQ
- Los Angeles, CA, United States
- Founded
- 2018
- Employees
- 186
- Website
- prenuvo.com/
- Ownership
- Privately Held (backing)
Prenuvo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Prenuvo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Prenuvo in its N-PORT filings yet. We sweep new filings monthly.